| Primary |
| Hepatitis B |
63.4% |
| Hepatic Cirrhosis |
13.0% |
| Product Used For Unknown Indication |
7.3% |
| Chronic Hepatitis B |
3.3% |
| Hepatic Cancer |
2.4% |
| Antiviral Treatment |
1.6% |
| Drug Use For Unknown Indication |
1.6% |
| Hypertension |
1.6% |
| Liver Injury |
1.6% |
| Anorexia |
0.8% |
| Diabetes Mellitus |
0.8% |
| Hepatitis |
0.8% |
| Jaundice |
0.8% |
| Non-hodgkin's Lymphoma |
0.8% |
|
| Transaminases Increased |
13.3% |
| Product Quality Issue |
12.0% |
| Aspartate Aminotransferase Increased |
6.7% |
| Drug Exposure During Pregnancy |
6.7% |
| Hbv Dna Increased |
6.7% |
| Hepatitis B |
6.7% |
| Pyrexia |
5.3% |
| Viral Hepatitis Carrier |
5.3% |
| Nausea |
4.0% |
| Nephrolithiasis |
4.0% |
| Splenomegaly |
4.0% |
| Thrombocytopenia |
4.0% |
| Albuminuria |
2.7% |
| Discomfort |
2.7% |
| Fatigue |
2.7% |
| Haemolytic Anaemia |
2.7% |
| Malaise |
2.7% |
| Osteonecrosis |
2.7% |
| Pain In Extremity |
2.7% |
| Pharyngitis |
2.7% |
|
| Secondary |
| Hepatitis B |
79.5% |
| Hepatic Cirrhosis |
11.4% |
| Liver Injury |
6.8% |
| Chronic Hepatitis B |
2.3% |
|
| Product Quality Issue |
13.5% |
| Transaminases Increased |
10.8% |
| Drug Resistance |
8.1% |
| Cachexia |
5.4% |
| Drug Ineffective |
5.4% |
| Fatigue |
5.4% |
| Hepatic Cirrhosis |
5.4% |
| Hepatitis |
5.4% |
| Osteomalacia |
5.4% |
| Rash |
5.4% |
| Vomiting |
5.4% |
| Alanine Aminotransferase Increased |
2.7% |
| Asthenia |
2.7% |
| Blood Creatine Phosphokinase Increased |
2.7% |
| Dysphagia |
2.7% |
| Haematemesis |
2.7% |
| Hepatitis B Dna Increased |
2.7% |
| Myalgia |
2.7% |
| Pancytopenia |
2.7% |
| Portal Vein Dilatation |
2.7% |
|
| Concomitant |
| Diabetes Mellitus |
22.2% |
| Hepatic Neoplasm Malignant |
22.2% |
| Hepatitis B |
22.2% |
| Liver Transplant |
22.2% |
| Hepatic Function Abnormal |
11.1% |
|
| Jaundice Cholestatic |
40.0% |
| Liver Transplant Rejection |
40.0% |
| Leukopenia |
20.0% |
|
